{"organizations": [], "uuid": "fc4539e5859b6813f8acd871fc4bbd0eaea43216", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180509.html", "section_title": "Archive News &amp; Video for Wednesday, 09 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biospecifics-technologies-reports/brief-biospecifics-technologies-reports-q1-earnings-per-share-0-54-idUSASC0A0Z7", "country": "US", "domain_rank": 408, "title": "BRIEF-Biospecifics Technologies Reports Q1 Earnings Per Share $0.54", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.835, "site_type": "news", "published": "2018-05-09T20:12:00.000+03:00", "replies_count": 0, "uuid": "fc4539e5859b6813f8acd871fc4bbd0eaea43216"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biospecifics-technologies-reports/brief-biospecifics-technologies-reports-q1-earnings-per-share-0-54-idUSASC0A0Z7", "ord_in_thread": 0, "title": "BRIEF-Biospecifics Technologies Reports Q1 Earnings Per Share $0.54", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "biospecifics technologies corp", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "biospecifics", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "co", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 9 (Reuters) - Biospecifics Technologies Corp:\n* BIOSPECIFICS TECHNOLOGIES CORP. REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS\n* Q1 REVENUE $7.1 MILLION VERSUS $7.7 MILLION * BIOSPECIFICS - AS OF MARCH 31, 2018, CO HAD CASH AND CASH EQUIVALENTS AND INVESTMENTS OF $64.2 MILLION, COMPARED TO $65.1 MILLION AS OF DEC 31, 2017\n* BIOSPECIFICS - CO’S CASH, CASH EQUIVALENTS WERE SLIGHTLY LOWER DUE TO THE TIMING OF ENDO’S PAYMENT OF ITS QTRLY XIAFLEX ROYALTIES Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-09T20:12:00.000+03:00", "crawled": "2018-05-10T17:19:35.016+03:00", "highlightTitle": ""}